Lilly Maps Out China Strategy
This article was originally published in PharmAsia News
Executive Summary
Last year, even as the worldwide pharmaceutical market growth slowed down to 3.8 percent, China powered ahead with a 15 percent increase. Eli Lilly's Chairman and CEO, Sidney Taurel, revealed that the company's business in China grew by 28 percent, which greatly fueled the overall corporate global performance. China Lilly is shifting its strategy from a FIPCO (Fully Integrated Pharmaceutical Company) model to FIPNET (Fully Integrated Pharmaceutical Network) model, which emphasizes collaboration rather than acquisition. The MNC has pumped investment into its China office as well as three local enterprises in Shanghai. Lilly China is exploring opportunities in community hospitals and will participate in drug tenders called by such organizations. (Click here for more - Chinese Language)